News
In this category you will find the latest insights from evitria as well as current press releases.
Articles about News (14)
-
Engineering bispecific antibodies
Recorded Presentation: From mAb to bAb Developing drugs requires navigating complex technical, practical, and strategic challenges quickly. Optimizing a drug’s activity and effectiveness and subsequently considering the IP landscape are crucially important balancing acts. Here, we demonstrate how evitria’s extensive expertise in antibody production can help you engineer, reformat, and produce your therapeutic, using a […]
-
evitria and Lonza Sign License Agreement to Provide Fast Access to bYlok® Bispecific Antibodies for Discovery-Stage Transient Expression Research
evitria AG, a global antibody expression service provider located in Zurich, Switzerland, has entered into a non-exclusive bYlok® bispecific pairing technology license agreement with Lonza. Lonza’s bYlok® bispecific pairing technology redefines IgG-like bispecific antibody design with simplicity and confidence to drive correct heavy-light chain (HC-LC) pairing.
-
Dr. Desmond Schofield new CBO of evitria
Dr. Desmond Schofield, has been appointed Chief Business Officer as of 1st January 2024.
-
Have you recently cited evitria in your research? We say thank you – with a discount!
evitria is both proud and grateful to be a frequently chosen research partner. Find out how we express our gratitude when being cited in your publication!
-
Bespoke solutions for lead selection and optimization in cancer antibody research
In this Webinar, Richard Park from evitria, will present Case Studies on Flexibility: Bespoke Solutions for Lead Selection & Optimization in Cancer Antibody Research – get your video now!
-
The Shortcut to Reliable Diagnostic, Control, and Assay Antibodies
In this webinar, we present a single integrated workflow for antibody sequencing and recombinant expression of mAbs. We will present a case study of a successful mAb-to-rAb conversion, describe the methodology in detail, and explain how it can be used to efficiently convert a catalog of mAb or pAb reagents into recombinant antibodies.
-
Dr. Stefan Schmidt new CEO of evitria
As of May 2023, Dr. Stefan Schmidt will take over the position of CEO at evitria. Read more about Dr. Schmidt and his vision for the company in this article.
-
Schweizer Expertise weltweit gefragt – evitria setzt Wachstumskurs fort
Das Team von evitria blickt auf Meilensteine und Errungenschaften zurück und setzt das Wachstum des Unternehmens auch 2023 fort.
-
Purification of His-tagged proteins
Proteins tagged with 4-10 histidine (His) residues can be purified using Immobilized Metal Affinity Chromatography (IMAC). This technique utilizes imidazole rings present on histidine side chains to non-covalently bind to the positively charged metal ions within an IMAC resin. IMAC purification can be used to purify proteins in their native conformation as well as under denaturing conditions.
-
20,000 antibodies purified – major milestone at evitria
With more than 20,000 abs and proteins purified, evitria has reached a huge milestone. Read more about its significance and our plans for the future.
